top of page

Greater Manchester diagnostics innovation programme secures over £14m investment

A health innovation programme to advance the use of novel diagnostics across Greater Manchester has been boosted by over £6m investment from life sciences, digital and creative industry partners, as well as £7.7m from Innovate UK, the UK’s national innovation agency.

Over the next two years, the health innovation accelerator will focus on tackling some of the most challenging disease areas through early diagnosis using novel approaches and holistic treatment aligned to people’s specific needs. It is hoped this will help to save more lives and improve health outcomes for people at high risk or living in the most disadvantaged communities.

The £14m programme includes a range of projects in diagnosing liver disease, heart failure, lung cancer, chest pain and cardiometabolic conditions, as well as the ground-breaking DEVOTE programme, to deliver bedside genomic tests to prevent a second stroke in a patient who has experienced a stroke; rapid point of care devices to detect genetic changes; and the development of a ‘pharmacogenetic passport’ to improve the effectiveness and safety of medicines for patients.

The health innovation accelerator is delivered through a partnership between Health Innovation Manchester, Manchester University NHS Foundation Trust, and the University of Manchester.

Further partnerships with global organisations and SMEs in life sciences, digital and creative industries have also been secured to provide additional expertise in technology and analytics, diagnostics and genomics, user research and marketing. The novel approach to industry partnerships testament to the strength of the city-region’s existing collaborations with life sciences and digital businesses.

The industry partners are as follows:

  • Diagnostic delivery partners include Sollis; Graphnet Health; Gendius; Jiva AI; Mindfield Advertising; By Gamers for Gamers; BCN Group.

  • The genomics project key partners are APIS Assay Technologies; EMQN CIC; Genedrive; Epinal; Chromition; and NW Genomic Medicine Alliance Service.

  • The diagnostics co-investment partners are AstraZeneca; Novartis; Boehringer-Ingelheim; MSD; Roche Diagnostics; MyCardium AI; Siemens; and Dedalus.

Funding from Innovate UK has been provided through Greater Manchester’s Innovation Accelerator programme. Led by Innovate UK on behalf of UK Research and Innovation, the pilot Innovation Accelerator programme is investing £100m in 26 transformative R&D projects to accelerate the growth of three high-potential innovation clusters – Glasgow City Region, Greater Manchester and West Midlands.

Laura Rooney, Director of Strategy at Health Innovation Manchester, said: “The health innovation accelerator programme will develop a step-change in the development and deployment of novel diagnostics in GM, targeted towards the needs of local people. It will add value to academic research and sector strengths and leverage existing data assets to transform patient care, unlock new market opportunities for businesses, and strengthen GM’s position as a world-leading centre for health innovation.”

bottom of page